Our unadjusted ITT analyses (3.21% of observations were imputed) of a combined daily BEP supplement and IFA tablet indicated a nonsignificant difference in maternal Hb concentration (0.02 g/dL; 95% CI: −0.09, 0.14 g/dL; P = 0.701), anemia (1.01 pp; 95% CI: −3.60, 5.60 pp; P = 0.665), or severe anemia prevalence (0.12 pp; 95% CI: −0.11, 0.35 pp; P = 0.319) at ANC 3, as compared with an IFA tablet alone (Table 2). This evidence concerns the gene GSTM1 and anemia (phenotype).